Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type 2 Diabetes AND Diabetes Mellitus, on Oral Hypoglycemic Treatment AND Diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    108 result(s) found for: Type 2 Diabetes AND Diabetes Mellitus, on Oral Hypoglycemic Treatment AND Diabetes. Displaying page 4 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2009-009500-39 Sponsor Protocol Number: H8O-EW-GWDM Start Date*: 2009-06-18
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects wit...
    Medical condition: Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PT (Completed) SE (Completed) FI (Completed) ES (Completed) NL (Completed) BE (Completed) IT (Completed) GR (Completed) EE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002618-11 Sponsor Protocol Number: I8F-MC-GPGM Start Date*: 2019-05-06
    Sponsor Name:Eli Lilly and Company
    Full Title: Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011965-10 Sponsor Protocol Number: AT130-G-08-006 Start Date*: 2009-08-14
    Sponsor Name:Akros Pharma Inc.
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study Evaluating the Efficacy, Safety and Tolerability of JTT-130 Administered Twice Daily for 24 Weeks in Tre...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    11.1 10012601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001253-82 Sponsor Protocol Number: I2R-MC-BIAO Start Date*: 2011-12-02
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAO The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double-Blind, Randomized, 52 Week Study ...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) LT (Completed) BE (Completed) ES (Completed) IE (Completed) DK (Completed) GR (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2005-004589-18 Sponsor Protocol Number: MKC-TI-105 Start Date*: 2006-08-16
    Sponsor Name:MannKind Corporation
    Full Title: Ensayo clínico de fase 3, de 12 meses de tratamiento, multicéntrico, aleatorizado, abierto, de grupo paralelo que compara insulina subcutánea prandial con insulina prandial inhalada Technosphere®/I...
    Medical condition: Diabetes mellitus tipo 1 o tipo 2
    Disease: Version SOC Term Classification Code Term Level
    7.1 10012601 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000145-35 Sponsor Protocol Number: 0431-803 Start Date*: 2008-04-25
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabete...
    Medical condition: type II diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) DK (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019223-55 Sponsor Protocol Number: H9X-MC-GBDD Start Date*: 2010-07-12
    Sponsor Name:Lilly S.A.
    Full Title: Comparación del efecto de LY2189265 frente a insulina glargina, administrados en combinación con insulina lispro, para el tratamiento hasta alcanzar el objetivo, en pacientes con diabetes mellitus ...
    Medical condition: Diabetes Mellitus Tipo 2
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-007034-36 Sponsor Protocol Number: A2171086 Start Date*: 2007-11-22
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY10017
    Full Title: A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENT...
    Medical condition: Diabetes mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009157-24 Sponsor Protocol Number: BC21893 Start Date*: 2009-06-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio multicéntrico, randomizado, doble ciego, con doble enmascaramiento,  controlado frente a un comparador activo para evaluar la eficacia, seguridad y tolerancia de taspoglutida (RO5073031) co...
    Medical condition: Pacientes con diabetes mellitus tipo 2 Patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    9 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004944-39 Sponsor Protocol Number: NPJ005-DM2-0522 Start Date*: 2018-04-27
    Sponsor Name:neopharma Japan Co., Ltd
    Full Title: A 24 Week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo-controlled, Proof of Concept Study to Assess the Efficacy and Safety of Two Doses of 5 Aminolevulinic Acid Co-administered wi...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000564-16 Sponsor Protocol Number: MKC-TI-134 Start Date*: 2013-08-14
    Sponsor Name:MannKind Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Dise...
    Medical condition: Type 1 or type 2 diabetes mellitus and underlying asthma or COPD.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004926-26 Sponsor Protocol Number: PRV-031-001 Start Date*: 2019-11-21
    Sponsor Name:Provention Bio, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in ...
    Medical condition: Type 1 Diabetes (T1D)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) FR (Completed) FI (Ongoing) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001861-25 Sponsor Protocol Number: DIAGNODE-2(D/P2/17/6) Start Date*: 2017-06-22
    Sponsor Name:Diamyd Medical AB
    Full Title: A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact ...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000842-39 Sponsor Protocol Number: I2R-MC-BIAJ Start Date*: 2011-10-26
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I2R-MC-BIAJ (a) A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin Naïve Patients with Type 2 ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed) CZ (Completed) DE (Completed) LT (Completed) ES (Completed) GR (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005174-56 Sponsor Protocol Number: 12R-MC-BIDD Start Date*: 2014-05-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study: The IMAGIN...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004864-29 Sponsor Protocol Number: F3Z-EW-IOPJ Start Date*: 2008-02-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003721-18 Sponsor Protocol Number: CV181365 Start Date*: 2015-09-14
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long -term Extension Period to Evaluate the Efficacy and Saf...
    Medical condition: Inadequately controlled Diabetes Mellitus Type 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) SE (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-016382-29 Sponsor Protocol Number: P1736-05/34/09 Start Date*: 2009-11-06
    Sponsor Name:Piramal Life Sciences Limited
    Full Title: A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects wi...
    Medical condition: Diabetes mellitus, type 2 (Blood Glucose Lowering Effect)/
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003843-12 Sponsor Protocol Number: PP-CT01 Start Date*: 2017-01-16
    Sponsor Name:PILA PHARMA
    Full Title: A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes me...
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002685-70 Sponsor Protocol Number: 300A Start Date*: 2015-08-03
    Sponsor Name:Lund University
    Full Title: The Effect of Sitagliptin on Glucagon Dynamics and Incretin Hormones During Mild Hypoglycemia in Elderly Patients with Metformin-Treated Type 2 Diabetes
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 15 23:35:39 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA